Olanzapine [132539-06-1]
O4400
Estimated Purity≥99%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameOlanzapine [132539-06-1]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥99%
- Format1mg/ml in ethanol, 16mg/ml in DMSO, and 20 mg/ml in DMF, sparingly soluble in aqueous buffers
- Scientific DescriptionAMPK activator, D1-4, 5-HT1A/2/3/6/7, M1-5 mAChR, alfa1/2-adrenergic antagonist.
- Storage InstructionAmbient
- UNSPSC12352200
References
- Ikegami M, Ikeda H, Ishikawa Y, et al. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus. Eur J Pharmacol. 2013 Aug 22. [Epub ahead of print]. PMID: 23973646. Cheon Y, Park JY, Modi HR, et al. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain. J Neurochem. 2011 Oct;119(2):364-76. PMID: 21812779. Lee JG, Cho HY, Park SW, et al. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1001-6. PMID: 20546816. Sepede G, De Berardis D, Gambi F, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. PMID: 16475705. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. PMID: 8822531.